Rituximab, a CD20-specific monoclonal antibody that depletes B cells, has shown promising results in patients with relapsing-remitting multiple sclerosis. Studies of experimental autoimmune ...

"The most significant finding here is the confirmation that our B-cell therapies not only can activate tumor-killing CD8 T cells, but a subset of them can infiltrate the tumor and produce ...

It is likely that B-cell-derived regulatory IL-10 has evolved to serve distinct immune functions, and that these functions are in turn carefully regulated in a cell-subset- and context-dependent ...

Completes Transition to Immune-Mediated Disease Focused CompanyHighlights Additional Data from Phase 1b Primary Membranous ...

Findings suggest the potential for obe-cel treatment without the need for consolidative SCTObe-cel given as a sole treatment to patients with ...

Researchers at Kyushu University have discovered a vital role for calcium in getting rid of dead cells in our body’s ...

Antibodies against B cells Rituximab is a depleting antibody ... This agent has been studied in a variety of RA patients subsets as both monotherapy and in combination with methotrexate.

By Pooja Toshniwal Paharia Study reveals that moderate fever temperatures (39°C) improve metabolism, proliferation, and ...

Dual Immunotherapy Plus Chemotherapy Benefits Specific Subset of Patients With Lung Cancer Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

Fever temperatures rev up immune cell metabolism, proliferation and activity, but they also—in a particular subset of T cells—cause mitochondrial stress, DNA damage and cell death, Vanderbilt ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...